“Working with Frazier when times were tough in a prior company gave me insight into their rare character and high integrity. Not only are they smart, low ego and not afraid to think big, they genuinely care about supporting their CEOs and companies.”
“The Frazier team really distinguish themselves by being true partners to their companies. They have supported us every step of the way with resources, guidance and expertise as we built the company.”
“Frazier has been a long-standing partner to Krystal since our IPO in 2017. They are a firm of high intellect and integrity, and I truly value their support as we evolved from an idea into a fully integrated biotechnology company.”
across venture and public strategies since 2015 to support innovation at every stage.
since 2015, leveraging in-house team and infrastructure.
since 2015 representing >$75B in cumulative transaction value.
from portfolio companies since 2015 including advances in oncology, orphan diseases, and other major therapeutic areas.
who bring seasoned investing experience and a collaborative approach to working with entrepreneurs and management teams.
Certain statements about Frazier Life Sciences made by portfolio company executives herein are intended to illustrate the work of Frazier’s team with such portfolio companies. Portfolio company executives were not compensated in connection with their participation, although they generally receive compensation and investment opportunities in connection with their portfolio company roles, and in certain cases are also owners of portfolio company securities, Senior Advisors, and/or investors in Frazier-sponsored vehicles. Such compensation and investments subject participants to potential conflicts of interest in making the statements herein.
1001 Page Mill Road
Building 4, Suite 200B
Palo Alto, CA 94304
650-325-5156
11455 El Camino Real, Suite 470
San Diego, CA 92130
100 Federal Street, 19th Floor
Boston, MA 02110
1700 Seventh Ave, Suite 1120
Seattle, WA 98101
